Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis von Snyder, Alexandra, Nathanson, Tavi, Funt, Samuel A, Ahuja, Arun, Buros Novik, Jacqueline, Hellmann, Matthew D, Chang, Eliza, Aksoy, Bulent Arman, Al-Ahmadie, Hikmat, Yusko, Erik, Vignali, Marissa, Benzeno, Sharon, Boyd, Mariel, Moran, Meredith, Iyer, Gopa, Robins, Harlan S, Mardis, Elaine R, Merghoub, Taha, Hammerbacher, Jeff, Rosenberg, Jonathan E, Bajorin, Dean F

Volltext

The biology and rationale of targeting nectin-4 in urothelial carcinoma von Heath, Elisabeth I., Rosenberg, Jonathan E.

Volltext

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial von Sharma, Padmanee, Prof, Callahan, Margaret K, MD, Bono, Petri, MD, Kim, Joseph, MD, Spiliopoulou, Pavlina, MD, Calvo, Emiliano, MD, Pillai, Rathi N, MD, Ott, Patrick A, MD, de Braud, Filippo, Prof, Morse, Michael, Prof, Le, Dung T, MD, Jaeger, Dirk, MD, Chan, Emily, MD, Harbison, Chris, PhD, Lin, Chen-Sheng, PhD, Tschaika, Marina, MD, Azrilevich, Alex, PharmD, Rosenberg, Jonathan E, MD

Volltext

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma von Powles, Thomas, Rosenberg, Jonathan E, Sonpavde, Guru P, Loriot, Yohann, Durán, Ignacio, Lee, Jae-Lyun, Matsubara, Nobuaki, Vulsteke, Christof, Castellano, Daniel, Wu, Chunzhang, Campbell, Mary, Matsangou, Maria, Petrylak, Daniel P

Volltext

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy von Rosenberg, Jonathan E, O'Donnell, Peter H, Balar, Arjun V, McGregor, Bradley A, Heath, Elisabeth I, Yu, Evan Y, Galsky, Matthew D, Hahn, Noah M, Gartner, Elaina M, Pinelli, Juan M, Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P

Volltext

Levi-Civita's Theorem for Noncommutative Tori von Rosenberg, Jonathan

Volltext

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers von Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M, Kania, Brooke E, Moran, Meredith M, Cipolla, Catharine K, Bluth, Mark J, Chaim, Joshua, Al-Ahmadie, Hikmat, Snyder, Alexandra, Carlo, Maria I, Solit, David B, Berger, Michael F, Funt, Samuel, Wolchok, Jedd D, Iyer, Gopa, Bajorin, Dean F, Callahan, Margaret K, Rosenberg, Jonathan E

Volltext

NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate von Teo, Min Yuen, Rosenberg, Jonathan E

Volltext

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons von Funt, Samuel A., Rosenberg, Jonathan E.

Volltext

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets von Pietzak, Eugene J, Bagrodia, Aditya, Cha, Eugene K, Drill, Esther N, Iyer, Gopa, Isharwal, Sumit, Ostrovnaya, Irina, Baez, Priscilla, Li, Qiang, Berger, Michael F, Zehir, Ahmet, Schultz, Nikolaus, Rosenberg, Jonathan E, Bajorin, Dean F, Dalbagni, Guido, Al-Ahmadie, Hikmat, Solit, David B, Bochner, Bernard H

Volltext

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma von Audenet, François, Isharwal, Sumit, Cha, Eugene K, Donoghue, Mark T A, Drill, Esther N, Ostrovnaya, Irina, Pietzak, Eugene J, Sfakianos, John P, Bagrodia, Aditya, Murugan, Paari, Dalbagni, Guido, Donahue, Timothy F, Rosenberg, Jonathan E, Bajorin, Dean F, Arcila, Maria E, Hechtman, Jaclyn F, Berger, Michael F, Taylor, Barry S, Al-Ahmadie, Hikmat, Iyer, Gopa, Bochner, Bernard H, Coleman, Jonathan A, Solit, David B

Volltext

Treatment Outcomes of Immune-Related Cutaneous Adverse Events von Phillips, Gregory S, Wu, Jennifer, Hellmann, Matthew D, Postow, Michael A, Rizvi, Naiyer A, Freites-Martinez, Azael, Chan, Donald, Dusza, Stephen, Motzer, Robert J, Rosenberg, Jonathan E, Callahan, Margaret K, Chapman, Paul B, Geskin, Larisa, Lopez, Adriana T, Reed, Vanessa A, Fabbrocini, Gabriella, Annunziata, Maria Carmela, Kukoyi, Oluwaseun, Pabani, Aliyah, Yang, Chih-Hsun, Chung, Wen-Hung, Markova, Alina, Lacouture, Mario E

Volltext

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer von van Dijk, Nick, Funt, Samuel A., Blank, Christian U., Powles, Thomas, Rosenberg, Jonathan E., van der Heijden, Michiel S.

Volltext

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer von Hoimes, Christopher J, Flaig, Thomas W, Milowsky, Matthew I, Friedlander, Terence W, Bilen, Mehmet Asim, Gupta, Shilpa, Srinivas, Sandy, Merchan, Jaime R, McKay, Rana R, Petrylak, Daniel P, Sasse, Carolyn, Moreno, Blanca Homet, Yu, Yao, Carret, Anne-Sophie, Rosenberg, Jonathan E

Volltext

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial von Bellmunt, Joaquim, Hussain, Maha, Gschwend, Jürgen E, Albers, Peter, Oudard, Stephane, Castellano, Daniel, Daneshmand, Siamak, Nishiyama, Hiroyuki, Majchrowicz, Martin, Degaonkar, Viraj, Shi, Yi, Mariathasan, Sanjeev, Grivas, Petros, Drakaki, Alexandra, O'Donnell, Peter H, Rosenberg, Jonathan E, Geynisman, Daniel M, Petrylak, Daniel P, Hoffman-Censits, Jean, Bedke, Jens, Kalebasty, Arash Rezazadeh, Zakharia, Yousef, van der Heijden, Michiel S, Sternberg, Cora N, Davarpanah, Nicole N, Powles, Thomas

Volltext

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells von Mariathasan, Sanjeev, Turley, Shannon J., Nickles, Dorothee, Castiglioni, Alessandra, Yuen, Kobe, Wang, Yulei, Kadel III, Edward E., Koeppen, Hartmut, Astarita, Jillian L., Cubas, Rafael, Jhunjhunwala, Suchit, Banchereau, Romain, Yang, Yagai, Guan, Yinghui, Chalouni, Cecile, Ziai, James, Şenbabaoğlu, Yasin, Santoro, Stephen, Sheinson, Daniel, Hung, Jeffrey, Giltnane, Jennifer M., Pierce, Andrew A., Mesh, Kathryn, Lianoglou, Steve, Riegler, Johannes, Carano, Richard A. D., Eriksson, Pontus, Höglund, Mattias, Somarriba, Loan, Halligan, Daniel L., van der Heijden, Michiel S., Loriot, Yohann, Rosenberg, Jonathan E., Fong, Lawrence, Mellman, Ira, Chen, Daniel S., Green, Marjorie, Derleth, Christina, Fine, Gregg D., Hegde, Priti S., Bourgon, Richard, Powles, Thomas

Volltext

Antibody-Drug Conjugates in Urothelial Carcinomas von Sarfaty, Michal, Rosenberg, Jonathan E.

Volltext

Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma von Aggen, David H., Rosenberg, Jonathan E.

Volltext

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 von RINI, Brian I, HALABI, Susan, SMALL, Eric J, ROSENBERG, Jonathan E, STADLER, Walter M, VAENA, Daniel A, ARCHER, Laura, ATKINS, James N, PICUS, Joel, CZAYKOWSKI, Piotr, DUTCHER, Janice

Volltext

Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use von Havlicek, David F, Rosenberg, Jonathan B, De, Bishnu P, Hicks, Martin J, Sondhi, Dolan, Kaminsky, Stephen M, Crystal, Ronald G

Volltext